Name : ClinTex (CTI)
CTI Price : $0.02 -3.25%
Consensus Mechanism : Token
Volume: 64,581
Market Cap: 2,441,906
Shariah Judgement
This feature only can be accessed by subscribed users.
Shariah Status :
Last Screening: Q1 2024
Legitimacy:
Project:
Token:
Reward:
Shariah
Legitimacy
People
Shariah Analysis
Project/Products | Use Case | Status |
---|---|---|
Use Case | Status |
---|---|
System | Status | Interpretation |
---|---|---|
Legitimacy Analysis
Details | Status | |
---|---|---|
Whitepaper | ||
Project |
People Analysis
Details | Status | |
---|---|---|
Team |
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Overview
ClinTex is a pioneering solution provider for the pharmaceutical and academic medical research industry, offering an innovative ecosystem called Clinical Trials Intelligence (CTi). Through cutting-edge clinical data analytics services, ClinTex drives efficiencies in clinical trial conduct and oversight. The CTi ecosystem identifies and eliminates trial bottlenecks in real-time, leveraging advanced analytics to predict potential issues before they impact trial performance. With intuitive operational oversight, enhanced data visualizations, predictive analytics, risk-based monitoring, artificial intelligence, and patient recruitment and retention management, ClinTex revolutionizes the way clinical trials are managed, ensuring faster, safer, and smarter development of new medicines.
Whitepaper & Documents
Sharlife uses TradingView technology to present price information through charts. TradingView serves as a charting platform catering to a worldwide community of traders and investors. With robust support across browsers, desktops, and mobile applications, the platform offers exceptional access to real-time data such as Dow Futures and BTC USD Chart, as well as the latest news, financial reports, stock screener, and economic .
COMMENTS
0 Comments